 Home > Medical News > Latest Medical News > Gracell GC012F First Human Clinical Trial Completes First Patient Dosing

Gracell GC012F First Human Clinical Trial Completes First Patient Dosing

 Last Update: 2022-03-05
 Source: Internet
 Author: User

Tags

laminin cell

celebrex drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Gracell Biotechnology Group (NASDAQ: GRCL; referred to as "Gracil Bio") today announced that it has launched a new evaluation of the company's core product candidate BCMA/CD19 dual-target autologous CAR-T cell therapy GC012F.

This investigator-initiated Phase I clinical trial (IIT) in China is an evaluation of the safety of GC012F in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

GC012F is a product candidate based on Gracell's proprietary FasTCAR platform technology, with the advantage of "next day production"; the therapy is currently in multiple Phase I clinical trials initiated by clinical investigators in China (IIT), including previously disclosed clinical studies in relapsed/refractory multiple myeloma

About GC012F

GC012F is a dual-targeted autologous CAR-T therapy candidate developed based on the FasTCAR platform

About B-Cell Non-Hodgkin Lymphoma (B-NHL)

Non-Hodgkin lymphomas (NHLs) are a class of hematological malignancies originating in lymph nodes and other lymphoid tissues, most commonly in B cells (B-NHL)

About FasTCAR

FasTCAR is Gracell's proprietary technology platform for the development of high-quality autologous CAR-T cell therapy

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Gracell Announces First-in-Human Clinical Trial of Its Dual-Target FasTCAR-T Cell Therapy GC012F for B-Cell Non-Hodgkin Lymphoma Completes First Patient Dosing

03-06

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Gracell GC012F First Human Clinical Trial Completes First Patient Dosing

Related Articles

Gracell Announces First-in-Human Clinical Trial of Its Dual-Target FasTCAR-T Cell Therapy GC012F for B-Cell Non-Hodgkin Lymphoma Completes First Patient Dosing